AdipoSeeds Inc. (Head office: Shinjuku-ku, Tokyo; CEO&CFO: Junji Fuwa; hereinafter referred to as “AdipoSeeds”), a Keio University-spun start-up working to commercialize ASCL- PLC[*1] , a multifunctional platelet derived from adipose tissue, has completed a third-party allotment of new shares to Daiwa Japan-Taiwan Bio Venture No. 2 Investment Limited Partnership, which is managed by DCI Partners Co., Ltd., and Sysmex Corporation.

 

AdipoSeeds and Sysmex Corporation are considering collaborating to combine AdipoSeeds’ technology and expertise related to the development of regenerative medicine products with Sysmex Corporation ‘s expertise and network in various sample testing assets and cell manufacturing, with the aim of improving quality and reducing the number of people required for quality control and manufacturing .

 

For the treatment of intractable skin ulcers (development code: ADS-01) , our proposal for “Development of human adipose-derived platelet-like cells (ASCL-PLC) as an allogeneic regenerative medicine product for the treatment of intractable skin ulcers” was adopted by the Japan Agency for Medical Research and Development (AMED) in its FY2024 “Drug Discovery Venture Ecosystem Strengthening Project.” With the funds raised this time, we aim to begin domestic Phase I/II clinical trials as soon as possible [*2] .

 

For transfusion platelets (development code: ADS-02), preparations are underway to begin an investigator-led study of “exploratory clinical research on human allogeneic adipose tissue-derived platelet-like cells for thrombocytopenia” at Institute of Science Tokyo, with the aim of verifying safety in humans, and the regenerative medicine provision plan has already been reviewed by the Special Certified Regenerative Medicine Committee of Institute of Science Tokyo [*3] . With the funds raised this time, we aim to begin the investigator-led study as soon as possible.

 

[About AdipoSeeds]

AdipoSeeds’ mission is to “create platelets from fat and create new blood flow.” The company aims to supply safe, medically applicable platelet preparations at low cost, primarily from human adipose tissue that would otherwise be discarded , and to contribute to resolving the problems relating to the accelerating global platelet shortage in the coming aging society together with a declining birthrate, thereby creating a future in which platelet-related medical treatments can be provided more cheaply and safely.

 

Furthermore, AdipoSeeds is working to solve the social problem of eliminating unmet medical needs by expanding the field of tissue repair using platelets through the “realization of regenerative medicine using platelets derived from adipose tissue.” In addition to working on the development of regenerative medicine products, AdipoSeeds is also engaged in a business related to PRP (Platelet Rich Plasma) therapy [*4], a type of regenerative medicine that utilizes the tissue repair capabilities of the growth factors of platelets contained in one’s own blood and the receptors expressed on the platelet membrane.

 

( *1) AdipoSeeds has established a mesenchymal stem cell line, ASCL (Adipose-derived Mesenchymal Stem Cell Line) , from a cell group containing ASCs (Adipose-derived Mesenchymal Stem Cells), which have been centrifuged from human subcutaneous adipose tissue using standard methods. This line is purified and established using a proprietary technology to overcome the shortcomings of ASCs. The line is then differentiated into ASCL-PLC (ASCL-derived Platelet-like Cells), and AdipoSeeds aims to apply ASCL-PLC to regenerative medicine and other medical applications .

 

( *2) In developing ASCL-PLC for the treatment of intractable skin ulcers, the investigator-led study has been conducted at Keio University Hospital, and the results were published on the following website . They show that no particular concerns were found regarding the safety of ASCL-PLC, and that a certain degree of effectiveness was observed, such as complete closure of ulcers within 12 weeks of administration.

 

Regenerative Therapy (Volume 30, December 2025, Pages 606-615)

 

(*3) The results of the review of the regenerative medicine provision plan by the Special Certified Regenerative Medicine Committee of Institute of Science Tokyo posted on the committee’s website below.

 

Summary of the 3rd Special Certified Regenerative Medicine Committee Meeting in 2025

 

(*4) Keio University Hospital has begun offering PRP therapy services with the aim of implementing evidence-based PRP therapy, and AdipoSeeds is providing technical support. Information about Keio University Hospital’s PRP therapy can be found on the following website:

 

Keio University Hospital PRP Outpatient Clinic

 

 

[Company Profile]

Company name	AdipoSeeds Inc.
Establishment	July 2016
Head office location	Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo
President and CEO	Junji Fuwa
Business overview	①　ASCL-PLC , a multifunctional platelet derived from adipose tissue (treatments for intractable skin ulcers, platelet preparations for transfusion, etc.) ② Business for PRP (Platelet Rich Plasma) therapy
Home page	http://www.adiposeeds.co.jp/

 

Company name	Sysmex Corporation
Establishment	February 1968
Head office location	1-5-1 Wakihama Kaigan-dori, Chuo-ku, Kobe , Hyogo
President	Kaoru Asano
Business overview	Development, manufacturing, sales, import and export of clinical testing equipment, testing reagents, and related software
Home page	https://www.sysmex.co.jp/

 

 

 

[Contact for inquiries regarding this release]

Junji Fuwa, CEO & CFO, AdipoSeeds, Inc.

TEL: +81-3-6822-0325 E-mail: info@adiposeeds.co.jp